- Slight quarterly miss on operating lines is a non-event - Acquisition potential remains, '25e CEPS...
Redeye comments on Raketech’s divestment of its US high-touch tipster advisory business as it increa...
Redeye provides its initial comments on Nanologica following its Q2 report that showed softer sales ...
On July 4, after trading closed on Oslo Børs, EG informed Carasent it will not proceed with an offer...
Q2e: Positive margin trends and cash flow We expect Q2 sales of EUR 42.
Q2e: return to growth as comps ease For Q2, we expect sales of SEK 45m, up 10% y-o-y, marking a retu...
Redeye comments on the final outcome of Modelon’s rights issue, giving the company SEK50.
Q2e: in line with Q1, easy y-o-y comps We expect Q2 sales of SEK 52m, up 26% y-o-y vs.
Rec PTP -7% vs ABGSCe, -8% y-o-y Fastpartner delivered a Q2 report with rental income of SEK 574m (-...
Redeye comments on Genovis following the announcement of a strategic investment in SEQURNA, a develo...
Reasons to be optimistic after slow start to the year We expect Elanders to report Q2 net sales of S...
Earnings capacity IFPM +3.5% vs ABGSCe Eastnine delivered a Q2 report with rental income of EUR 9.
Yesterday after close Acarix announced a SEK21m directed share issue targeting US based family offic...
Förvaltningsresultat ökade med 26% på årsbasis drivet av främst ränteintäkter.
Duell’s Q3 development was two-fold as growth in Europe was stronger than expected while revenue dec...
Q2'24e expectations We forecast flat (0%) organic growth rate for Vitrolife and a marginally higher ...
Redeye comments on AVTECH’s key figures, which came in 5% ahead on net sales and 25% on EBITDA, sugg...
Redeye comments on W5’s announcement of a major framework agreement for generators worth up to SEK50...
Redeye presents its preview for Devyser Diagnostics’ Q2 2024 report, due on July 23.
IRLAB Therapeutics has successfully completed the second and final of two pre-determined safety and ...
